Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticos...
Q2 2026
Aug 5, 2026
Q1 2026
May 6, 2026
FY 2025
Feb 25, 2026
Q4 2025
Q3 2025
Nov 5, 2025